Share Prices & Company Research

Stockbroking

Oxford BioMedica

Current Price 565.00p Bid 565.00p Ask 580.00p Change 0.53%
Last Updated: 11/11/2019 20:36. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Oxford BioMedica plc is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the Group) have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 430 people.

Financial Highlights Year Ended 31/12/2018

Turnover
£66.78m
Operating Profit
£13.92m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
48.57

Key Personnel

John Andrew Dawson
Chief Executive Officer
Stuart Paynter
Chief Financial Officer
Dr Lorenzo Tallarigo
Non-Executive Chairman
Dr Heather Elizabeth Preston
Non-Executive Director
Stuart Jonathon Brodie Henderson
Non-Executive Director
Dr Andrew John William Heath
Non-Executive Director
Robert Evgeniev Ghenchev
Non-Executive Director
Martin Henry Diggle
Non-Executive Director

Stock Details

EPIC
OXB
ISIN
GB00BDFBVT43
Shares in Issue
76,779,548
Market cap
£431.50m

Analyst Views (2)

Strong Buy
 
100.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
565.00p
Bid Price
565.00p
Ask Price
580.00p
Volume
54564
Change Today
3.00p
% Change Today
0.53%
Open
580.00p
Previous Close
565.00p
Intraday High
580.00p
Intraday Low
547.00p
52 Week High
793.00p
52 Week Low
461.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Oxford BioMedica Intra-day Chart

Oxford BioMedica News

News in this section is provided by AJ Bell

Broker Forecast - Liberum Capital issues a broker note on Oxford BioMedica PLC 30 Sep 2019 | 08:50 Director Deals - Oxford BioMedica PLC (OXB) 25 Sep 2019 | 13:40 Director Deals - Oxford BioMedica PLC (OXB) 16 Sep 2019 | 11:50 Director Deals - Oxford BioMedica PLC (OXB) 16 Sep 2019 | 11:35 Director Deals - Oxford BioMedica PLC (OXB) 13 Sep 2019 | 13:30 Director Deals - Oxford BioMedica PLC (OXB) 13 Sep 2019 | 13:30 Director Deals - Oxford BioMedica PLC (OXB) 13 Sep 2019 | 13:10 Oxford Biomedica losses deepen as sales fall, R&D costs rise 04 Sep 2019 | 07:39 Director Deals - Oxford BioMedica PLC (OXB) 23 Aug 2019 | 12:15 Director Deals - Oxford BioMedica PLC (OXB) 25 Jul 2019 | 14:45 Director Deals - Oxford BioMedica PLC (OXB) 26 Jun 2019 | 17:05 Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC 28 May 2019 | 08:00 Director Deals - Oxford BioMedica PLC (OXB) 23 Apr 2019 | 13:15 Director Deals - Oxford BioMedica PLC (OXB) 23 Apr 2019 | 13:15 Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC 15 Mar 2019 | 08:10 Director Deals - Oxford BioMedica PLC (OXB) 25 Feb 2019 | 12:50 Director Deals - Oxford BioMedica PLC (OXB) 06 Feb 2019 | 11:30 Director Deals - Oxford BioMedica PLC (OXB) 06 Feb 2019 | 11:30 Director Deals - Oxford BioMedica PLC (OXB) 05 Feb 2019 | 12:15 Director Deals - Oxford BioMedica PLC (OXB) 24 Jan 2019 | 11:45 Director Deals - Oxford BioMedica PLC (OXB) 18 Jan 2019 | 12:50 Director Deals - Oxford BioMedica PLC (OXB) 18 Jan 2019 | 12:50 Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC 04 Jan 2019 | 08:10 Director Deals - Oxford BioMedica PLC (OXB) 23 Nov 2018 | 12:10 Oxford BioMedica to invest £4m in digital framework project 23 Nov 2018 | 07:38

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
31.8
25.4
Intangible Assets & Goodwill
0.1
0.1
Investments & Other Non-Current Assets
11.0
3.0
Total Non-Current Assets
42.9
28.4
Inventory
4.3
3.3
Trade & Receivables
30.6
17.1
Cash & Receivables
32.2
14.3
Other Current Assets & Assets Held for Resale
2.5
2.2
Total Assets
112.4
65.4

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
28.5
21.8
Long Term Liabilities
49.2
37.5
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
77.7
59.3

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
34.7
6.2

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
33.0
31.1
Minority Interests
0.0
0.0
Retained Earnings
-173.9
-182.7
Share Premium Account
172.1
154.2
Other Equity
3.5
3.5
Total Equity
34.7
6.2

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
12.9
3.0
Cashflow Before Financing
2.8
1.1
Increase / Decrease in Cash
17.9
-1.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
66.8
37.6
Cost of Sales
22.8
18.4
Gross Profit
44.0
19.2
Operating Profit
13.9
-5.7
Pre-Tax Profit
5.0
-11.8
Profit / Loss for the Year
7.5
-9.0
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.